Drug intelligence / Profile preview

TOP3

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

TOP3 (TAT-ODD-procaspase-3) is a protein prodrug designed to target hypoxia-inducible factor (HIF)-active cancer cells. It is specifically processed and activated in these hypoxic cells, leading to cell death. This mechanism allows for targeted delivery and activation within the tumor microenvironment, which is often characterized by hypoxia. TOP3 has shown promise in improving survival in orthotopic pancreatic cancer models, particularly when combined with standard chemotherapeutic drugs like gemcitabine or TS-1.

Targets

CASP3 (Caspase-3)EGLN1 (Prolyl hydroxylase domain-containing protein 2)

Beyond the preview

Go deeper on TOP3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOP3.

Explore the full profile